Tag Archives: Nordisks

Novo Nordisk’s Woes Are Slimming Denmark’s Economic Growth  The New York Times Layoffs From Just 6 Pharmas Could Wipe Out Over 39,000 Jobs  BioSpace Exclusive: Novo Nordisk cuts US obesity education team as layoffs begin, say sources, online posts  Reuters Layoffs hit Novo Nordisk, Bristol Myers Squibb in NJ  NJBIZ Novo Nordisk Overhauls Senior Job Titles in Latest Shake-Up  Bloomberg.com Source link

Danish drugmaker Novo Nordisk (NVO), a top competitor to American pharmaceutical giant Eli Lilly (LLY), is currently exciting investors in Europe. The company’s stock price is up about 2% to $57.7 (DKK 365.35) as of 10:33 a.m. EDT on the Nasdaq Copenhagen Stock Exchange. On Germany’s Xetra, the shares also rose by 2.36% to $57 (EUR 48.94) as of 10:30 …

A sign with the company logo sits outside of the headquarters of Eli Lilly in Indianapolis, Indiana, on March 17, 2024. Scott Olson | Getty Images Eli Lilly‘s stock is still recovering after the drugmaker released trial data earlier this month on its closely watched obesity pill that underwhelmed Wall Street. In a key late-stage trial, Eli Lilly’s pill, orforglipron, caused …

Novo Nordisk’s obesity drug Wegovy was cleared by U.S. regulators on Friday to treat an increasingly common liver disease, adding to the list of conditions for which the blockbuster therapy is now approved.  The Food and Drug Administration granted accelerated approval to Wegovy for patients with metabolic dysfunction-associated steatohepatitis, or MASH, with moderate to advanced liver scarring. The decision was …

Novo Nordisk’s Wegovy Gets US Approval for Liver Disease  Bloomberg.com Novo Nordisk’s obesity drug Wegovy cleared to treat MASH  statnews.com Wegovy® approved by FDA for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis  PR Newswire Novo Nordisk A/S: Wegovy® approved in the US for the treatment of MASH  Yahoo Finance Novo Nordisk’s Wegovy gets accelerated US approval for liver …

Sales of Novo Nordisk’s injectable diabetes drugs including Ozempic have slowed sharply amid fierce competition and the threat of US tariffs, prompting it to cut costs and sharpen its commercial focus. The Danish drugmaker, whose booming sales of GLP-1 diabetes and obesity drugs in recent years had turned it into Europe’s most valuable company, has lost nearly $100bn (£75bn) in …

Novo Nordisk’s Earnings Come After a Dramatic Guidance Cut. What to Look for Now.  Barron’s Wegovy maker Novo Nordisk’s sales hike in second quarter  CNBC Novo Nordisk Before Q2 Earnings: How Should Investors Play the Stock?  Yahoo Finance Ozempic Maker’s Plight Shows Managing Markets Counts Too  Bloomberg.com Novo Nordisk is no longer a buy at UBS, which says compounding is here to stay  MarketWatch Source …